Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia-Reference-Cited by-同舟云学术

Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia

Published:2020-09-29 Issue:5 Volume:38 Page:754-762
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Borlenghi Erika¹^ORCID,Cattaneo Chiara¹,Cerqui Elisa¹,Archetti Silvana²,Bertoli Diego²,Bellotti Daniela³,Gramegna Doriana¹,Soverini Giulia¹,Oberti Margherita¹,Schieppati Francesca⁴,Pagani Chiara¹,Passi Angela¹,Sciumé Margherita¹,Farina Mirko¹,Carbone Cecilia¹,Crippa Claudia¹,Dalceggio Daniela¹,Tucci Alessandra¹,Rossi Giuseppe¹

Affiliation:

1. Hematology Department ASST Spedali Civili Brescia Italy

2. Diagnostic Department Clinical Chemistry Laboratory ASST Spedali Civili Brescia Italy

3. Laboratorio di Citogenetica e Genetica Medica ASST Spedali Civili Brescia Italy

4. Immunohematology and Trasfusion Medicine Hospital Papa Giovanni XXIII Bergamo Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2806

Reference37 articles.